The enzymatic activities of Furin, Transmembrane serine proteinase 2 (TMPRSS2), Cathepsin L (CTSL), and Angiotensin‐converting enzyme 2 (ACE2) receptor binding are necessary for the entry of coronaviruses into host cells. Precise inhibition of these key proteases in ACE2+ lung cells during a viral infection cycle should prevent viral S protein activation and its fusion with a host cell membrane, consequently averting virus entry to the cells. In this study, we construct dual‐drug‐combined (TMPRSS2 inhibitor Camostat and CTSL inhibitor E‐64d) nanocarriers (NCs) conjugated with an anti‐hACE2 antibody and employ RBC‐hitchhiking, termed “Nanoengineered RBCs,” for targeting lung cells. We report the significant therapeutic efficacy of the dual‐drug‐loaded nanoengineered RBCs in pseudovirus‐infected K18‐hACE2 transgenic mice. Notably, our modular nanoengineered RBCs (anti‐receptor antibody+NCs+RBCs) precisely target key proteases of host cells in the lungs to block the entry of SARS‐CoV‐2, regardless of virus variations. Our findings are anticipated to benefit the development of a series of novel and safe host‐cell‐protecting antiviral therapies.This article is protected by copyright. All rights reserved